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https://doi.org/10.1053/j.gastro.2019.05.007BACKGROUND & AIMS: Sofosbuvir is a frequently used pan-
genotype inhibitor of hepatitis C virus (HCV) polymerase.
This drug eliminates most chronic HCV infections, and
resistance-associated substitutions in the polymerase are
rare. However, HCV genotype 3 responds slightly less well
to sofosbuvir-based therapies than other genotypes. We
collected data from England’s National Health Service Early
Access Program to search for virus factors associated with
sofosbuvir treatment failure. METHODS: We collected pa-
tient serum samples and used the capture-fusion assay to
assess viral sensitivity to sofosbuvir in 14 HCV genotype 3
samples. We identified polymorphisms associated with
reduced response and created modified forms of HCV and
replicons containing the substitutions of interest and tested
their sensitivity to sofosbuvir and ribavirin. We examined
the effects of these polymorphisms by performing logistic
regression multivariate analysis on their association with
sustained virologic response in a separate cohort of 411
patients with chronic HCV genotype 3 infection who had
been treated with sofosbuvir and ribavirin, with or without
pegylated interferon. RESULTS: We identified a substitution
in the HCV genotype 3a NS5b polymerase at amino acid 150
(alanine [A] to valine [V]), V at position 150 was observed in
42% of patients) with a reduced response to sofosbuvir in
virus replication assays. In patients treated with sofosbuvir-
containing regimens, the A150V variant was associated with
a reduced response to treatment with sofosbuvir and riba-
virin, with or without pegylated interferon. In 326 patients
with V at position 150, 71% achieved an sustained virologic
response compared to 88% with A at position 150. In cells, V
at position 150 reduced the response to sofosbuvir 7-fold. We
found that another rare substitution, glutamic acid (E) at
position 206, significantly reduced the response to sofosbuvir
(8.34-fold reduction); the combinations of V at position 150
and E at position 206 reduced the virus response to sofos-
buvir 35.77-fold. Additionally, in a single patient, we identi-
fied 5 rare polymorphisms that reduced sensitivity to
sofosbuvir our cell system. CONCLUSIONS: A common poly-
morphism, V at position 150 in the HCV genotype 3a NS5b
polymerase, combined with other variants, reduces the virus
response to sofosbuvir. Clinically, infection with HCV geno-
type 3 containing this variant reduces odds of sustained
virologic response. In addition, we identified rarecombinations of variants in HCV genotype 3 that reduce
response to sofosbuvir.Keywords: mutation; amino acid change; genetics; response to
therapy.
-
ofosbuvir (SOF) is a highly effective antiviral drugSthat has replaced interferon (IFN) as the back-
bone of many therapies for patients with chronic hep-
atitis C virus (HCV) infection.1 In combination with
drugs targeting other viral enzymes (including the
poorly potent guanosine analogue, ribavirin [RBV],2 or
highly potent inhibitors of viral NS5a3 or protease
proteins4) most patients clear virus, and resistance
polymorphisms known to reduce SOF’s antiviral effects
are almost never observed,5 allowing effective retreat-
ment.6 The mechanism of treatment failure in the small
proportion of individuals who do not respond remains
unknown. The recent introduction of triple-therapy
regimens (SOF with a pan-genotypic protease and
NS5a inhibitors7,8) provides an alternative to the current
approach to therapy, which combines SOF with an NS5a
inhibitor alone.3,9 However, protease inhibitors are
contraindicated in patients with decompensated
cirrhosis, and in such patients, the only available ther-
apy is SOF plus an NS5a inhibitor. It is not known which
patients require triple therapy and it is not clear
whether this regimen should be reserved as a retreat-
ment option for the few patients who do not respond to
dual therapy.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Patients with genotype 3 HCV respond less well to
therapy with direct-acting antiviral agents and the
response is greatly reduced in patients with cirrhosis,
who often have fewer retreatment options. The
mechanisms for this reduced response are unclear.
NEW FINDINGS
The authors identified polymorphisms in genotype 3 HCV
(A150V and K206E) that reduce the response to
sofosbuvir. The A150V variant is common and K206E
variant is rare. Additional very rare polymorphisms
reduce the response in combination.
LIMITATIONS
Additional study is needed on the role of this
polymorphism in disease progression and sensitivity to
triple therapy
IMPACT
The authors identified a polymorphism in HCV genotype 3
that affects virus response to treatment. This discovery
could increase our understanding of mechanisms of
treatment failure and might change treatment regimens
for patients with HCV genotype 3 infection.
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and comprises 30% of all HCV infections in Eastern and
Western Europe.10 Patients infected with this genotype
respond well to IFN-based regimens, with response rates
approaching 80% in patients without cirrhosis, although the
response is greatly reduced in those with advanced
fibrosis.11,12 SOF is active against HCV genotype 3 and in
combination with the pan-genotypic NS5a inhibitor velpa-
tasvir,9 >90% of patients respond. However, response rates
with SOF/velpatasvir are lower in patients with cirrhosis
than in those with lesser degrees of fibrosis and the
response to therapy is further reduced in patients previ-
ously exposed to IFN-based therapies. For patients with
decompensated cirrhosis, for which protease inhibitors are
contraindicated, response rates for patients with genotype 3
may be as low as 50%.8 It is unclear why HCV genotype 3 is
less sensitive to SOF than other HCV genotypes, and it is not
known why prior therapy with IFN impacts response.
The extraordinary success of SOF-based treatments in
both clinical trials and real-world studies, with sustained
virologic response (SVR) rates of >95%, has reduced the
opportunity to study patients who do not respond—there are
very few patients to examine. Viral sequencing of this highly
polymorphic, rapidly evolving virus has, to date, not identi-
fied motifs clearly associated with a reduced response to SOF.
In vitro, a variant at position 282 (S282T polymorphism) is
commonly selected, although it does have a reduced repli-
cation capacity.13 In clinical studies, the S282T variant is
rarely seen14 and the “resistance polymorphisms” that have
been reported after antiviral therapy (L159F and V321A) do
not appear to reduce the effectiveness of SOF in viral repli-
cation models.15 Studies identifying treatment outcome of
pre-existing resistance variants in baseline clinical samplesshow that presence of variants susceptible to treatment can
dilute the effect of resistance variants to therapy.16 This
suggests that polymorphisms that reduce response to SOF
will be difficult to detect by sequence analysis alone. A more
informative approach would be to combine high-throughput
sequencing data with in vitro antiviral phenotyping of clin-
ical isolates to identify rare motifs that impact viral response
to SOF and other potent antiviral agents.
To address the issue of “SOF resistance,” we studied pa-
tients from the National Health Service England Early Access
Programme,17,18 which offered antiviral therapy with SOF,
RBV, and NS5a inhibitors (either daclatasvir [DAC] or ledi-
pasvir) to patients with advanced liver disease. The program
was initiated before drug licensing and used treatment du-
rations for HCV genotype 3 infection that, in retrospect, may
have been suboptimal, that is, 12 weeks, rather than the now
recommended 24 weeks. The high relapse rate (approxi-
mately 30%) in patients with HCV genotype 3 prompted a
search for viral factors associated with SOF treatment failure.
Methods
Study Samples
Serum and plasma samples from patients who donated sam-
ples to the HCV Research UK Biobank were used after informed
consent and approval by the Biobank Tissue Access Committee, as
approved by a UK Ethical Review Committee. Additional samples
were obtained after informed consent and Ethics Committee
approval from patients attending the Royal London Hospital.
In Vitro Analysis
Viral phenotyping was performed using the “capture-fusion”
viral replication assay in which infected serum is incubated with
monocytes before fusion of HCV containing monocytes with he-
patocytes.19 Library preparation, sequencing, assembly, and
variant detection are described in the Supplementary Methods.
Site-Directed Mutagenesis and Transfection
Hepatitis C Virus Replicon Constructs
Nucleotide changes were introduced into the genotype 3
S52-(SHI) sub-genomic replicon1 (a kind gift from Charlie Rice),
and the full-length genotype 3 DBN (a kind gift from Jens
Bukh)19 clone using the Quick-Change II XL site-directed
mutagenesis kit (Agilent, Santa Clara, CA). Nucleotide changes
were confirmed by Sanger sequencing (Cambridge Bioscience,
Cambridge, UK). Replicon plasmids were linearized with XbaI,
treated with mung bean nuclease, purified, and in vitro–
transcribed using the MEGAscript T7 Transcription kit
(Ambion, Austin, TX). For electroporation, cells were washed
twice with ice-cold phosphate buffered saline and diluted to a
concentration of 5  106 cells/mL. Five micrograms of purified
RNA was mixed with 400 mL cell suspension and electroporated
using a BioRad Genepulser II on the exponential setting (pulse
settings: 250V and 950 mF). To generate the stable replicon
cells, cells were grown with G418 (750 mg/mL). For antiviral
drug assays, cells were transferred to complete medium and
seeded into 96-well plates and left to recover for 24 hours.
Antiviral drugs were added for 72 hours, after which cells were
lysed in 1X passive lysis buffer and firefly luciferase activity
Figure 1. SOF sensitivity in
HCV genotype 3 treatment
non-responders to direct-
acting antiviral (DAA) ther-
apy was assessed using
the capture-fusion assay.
Sera from patients with
HCV genotype 3 (n ¼ 14)
who achieved SVR (blue)
or relapsed (red) were
used to assess sensitivity
to SOF and RBV. Changes
in HCV RNA for SOF and
RBV in patients who ach-
ieved SVR (n ¼ 4) (A, E) or
relapsed are shown. Sam-
ples from patients who
relapsed were further
divided into 2 groups,
depending on the assay
outcome, those who were
SOF- and RBV-sensitive
(n ¼ 4) (B, F) and insensi-
tive (n ¼ 6) (C, G). Data
were summarized in (D;
SOF) and (G; RBV) to show
HCV RNA as a percentage
of no drug treatment for a
single dose of drug (0.25
mM of SOF and 0.75 mM of
RBV). Graphs show mean
± SEM. P values were
calculated using Kruskal-
Wallis test. Drug sensi-
tivity of each sample was
assessed in quadruplicate
for each concentration.
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Madison, WI).Generation of Infectious Genotype 3 Derived
Cell Culture Hepatitis C Virus
Huh7.5-SEC14L2 cells were seeded in a 6-well plate at a
density of 4.2  105 cells/well 24 hours before transfection.Lipofectamine 3000 (3.75 mL) was diluted in 125 mL of Opti-
MEM and 5 mg of DBN3acc RNA was diluted in 250 mL of
OptiMEM. Both mixes were incubated at room temperature for
5 minutes before combining, after which the reaction mixture
was incubated for an additional 20 minutes at room tempera-
ture and then added drop wise to the cells. After 24 hours, cells
were placed in Dulbecco’s modified Eagle medium 10% fetal
calf serum and expanded into T25-cm2 then T75-cm2 flasks. At
Table 1. Identified Polymorphisms Within the NS5B of the Phenotypes Samples
Patient
no. Therapy
Therapy
outcome
Assay
outcome
(SOF)
Drug sensitivity Relevant polymorphisms, % (pre/post therapy)
SOF IC50, mM RBV IC50, mM K100R A150V A150S G188D K206E T213N N244I
1 SOF/DAC/RBV SVR Sensitive 0.039 0.786 — V (98) — — — — —
2 SOF/VEL SVR Sensitive 0.034 0.545 — — — — — — —
3 SOFþOBV /PTV/RBV SVR Sensitive 0.011 0.419 — — — — — — —
4 SOF/DAC SVR Sensitive 0.054 0.19 — — — — E (98) — —
5 SOF/LDV/RBV Relapse Sensitive 0.06 0.43 — — — — E (99) — —
6 SOF/DAC/RBV Relapse Sensitive 0.033 0.886 — — — — E (99) — —
7 SOF/LDV/RBV Relapse Sensitive 0.04 0.72 — V (98) — — — — —
8 SOF/LDV Relapse Sensitive 0.02 0.701 — — — — — — —
9 SOF/DAC/RBV Relapse Insensitive >0.25 >1.25 R (65/98) — S (98–99) D (98/97) — N (98/99) I (94–99)
10 SOF/LDV/RBV Relapse Insensitive >0.25 >1.25 R (97/98) V (54–98) — — E (89/99) — —
11 SOF/LDV/RBV Relapse Insensitive >0.25 >1.25 — V (98–95) — — E (98/99) — —
12 SOF/DAC/RBV Relapse Insensitive >0.25 >1.25 — V (98–97) — — E (100/99) — —
13 SOF/LDV/RBV Relapse Insensitive >0.25 >1.25 — V (98–99) — — E (98/99) — —
14 SOF/LDV/RBV Relapse Insensitive >0.25 >1.25 — V (99)a — — E (100)a — —
NOTE. Patients were divided into 3 groups (SVR-sensitive, relapse-sensitive, and relapse-insensitive) based on therapy and assay outcomes. Samples were deemed to be
SOF-insensitive if a single dose of the antiviral drug (0.25 mM) did not reduce the HCV RNA levels to <80% of the no-drug control in the capture fusion assay. Poly-
morphisms were identified by comparison of NS5b next-generation sequencing data from drug-sensitive vs drug-insensitive samples. The majority of the polymorphisms
were identified in the assay-insensitive group, with a specific pattern (A150V and K206E) seen in patients 10–14. Percentage values indicate the frequency of each
polymorphism present in the viral populations.
LDV, ledipasvir.
aNo post-treatment sequencing data were obtained for sample 14 due to low viral load post relapse.
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LIVER7 days post transfection, cells were seeded onto coverslips to
assess presence of HCV replication complexes by NS5a immu-
nofluorescence. Once >50% of cells were deemed to be positive
for HCV, supernatants from the transfected cells were filter-
sterilized using a 0.45-mm syringe filter, aliquoted, and stored
at –80C.Statistical Analysis
Multivariate logistic regression was used for the anal-
ysis of association between SVR and the viral poly-
morphisms A150V and K206E and to test for interaction
between the 2 sites and its impact on the SVR. To account
for population structure of the host and the virus,
we performed principal component analysis on host
genome-wide genotype data and on virus whole genome
nucleotide data. Two virus principal components and 3 host
principal components were used as covariates in the model
to account for the host and virus population structures. We
also added patients’ IFNL4 genotypes (CC vs non-CC),
cirrhosis status, and previous IFN-based treatment status
in our model as covariates to account for possible con-
founding. The multiple comparisons in the capture fusion
assay experiments were analyzed using Kruskal-Wallis
analysis and changes in drug sensitivity in replication as-
says were determined to be statistically significant if the
95% confidence intervals (CIs) did not overlap.Results
Viral Phenotyping Reveals Distinct Patterns of
Polymorphisms in Patients With a Reduced
Response to Sofosbuvir
We used the capture-fusion assay19 to assess SOF and
RBV sensitivity of 14 HCV genotype 3 samples. These
included pretreatment viral samples sourced from patients
with advanced liver disease from the National Health Ser-
vice England Early Access Programme (n ¼ 10) and 4
additional HCV genotype 3 samples from patients who had
either responded to therapy in the early access program
(n ¼ 2) or had previously shown a response to SOF in vitro
(n ¼ 2) and were later treated successfully. Samples from
SOF-treated patients were selected on the basis of viral load
(>1  105 IU/mL) and availability (Supplementary Table 1).
Sensitivity of samples was assessed by treatment of infected
cells with a range of SOF and RBV doses (0–0.25 mM and 0–
1.25 mM, respectively) and measurement of HCV RNA in
response to drug treatment (SOF, Figure 1A–D and RBV,
Figure 1E–G). These analyses were performed without prior
knowledge of treatment outcome. After unblinding, drug
sensitivity data for all samples tested were grouped into
treatment outcome. Samples from patients who achieved
SVR demonstrated a significant reduction in HCV RNA in
response to treatment with SOF (Figure 1A) and RBV
(Figure 1E). Note that in the capture-fusion assay, residual
signal leads to apparent detection of virus even at high
doses of inhibitor and hence viral replication does not fall to
zero. Data obtained from samples from patients who
relapsed showed 3 distinct patterns of response to SOF. Wedefined these as “relapse sensitive” or “relapse insensitive,”
based on an examination of the dose–response curves. Sig-
nificant reductions in HCV RNA were only seen in 4 samples
in response to SOF and RBV (Figure 1B and F, “sensitive”
sample), while the majority of samples from patients who
relapsed (n ¼ 6) exhibited no substantial change in HCV
RNA when treated with a range of SOF and RBV doses
(“insensitive” samples). To highlight the different drug
sensitivities between the sample groups, we analyzed the
percentage change in HCV RNA compared to the no-drug
control at individual doses of 0.25 mM SOF (Figure 1D)
and 0.75 mM RBV (Figure 1H). A mid-range dose of RBV was
selected for the comparison due to some cytotoxicicty at
high RBV concentrations (see Supplementary Figure 1).
Four viral samples from patients who relapsed showed a
comparable reduction in HCV RNA to samples from patients
who achieved SVR, while 6 of the 10 samples from patients
who relapsed showed no change in HCV RNA with SOF or
RBV treatment at this dose.
Samples were subjected to high-throughout, next-genera-
tion sequencing with substitutions present in <15% of the
sequencing reads discarded. Viral sequences were then
compared to the reference genotype 3a sequence
(NC_004102) (Table 1). No reported SOF resistance associ-
ated substitutions (L159F, S282T, or V321A20) were found,
but 5 of 6 SOF “insensitive” samples had polymorphisms in
domains 1 and 2 of the polymerase protein—A150V and
K206E—that were not seen in combination in the sensitive
samples, although the individual substitutions were observed.
The other SOF-insensitive patient had 5 changes, 4 of which
were unique (A150S, G188D, T213N, and N244I).Prevalence and Impact of NS5b Mutations in a
Second Patient Cohort
The reference sequences of the 7 HCV genotypes were
aligned and the amino acids at the polymorphisms of in-
terest were compared (Supplementary Figure 2A). Positions
150, 213, and 244 appeared to be the least conserved across
the genotypes. Alignment of 1200 HCV genotype 3a se-
quences from the HCV-GLUE database (a UK-based database
of published HCV sequences)21 (amino acids 91–250)
(Supplementary Figure 2B) showed that amino acids 150
and 206 were the least conserved of the positions of interest
and that amino acid 150, in particular, is highly poly-
morphic. In comparison, available sequences for HCV ge-
notype 3b in HCV-GLUE shows that alanine at position 150
is dominant (n ¼ 39/42). In HCV genotype 3a sequences,
alanine at position 150 is present at a frequency of 40.65%,
with the valine variant present at a frequency of 36.66%.
The variation at position 206 is much less pronounced, with
lysine (K) dominating at a frequency of 76.31% and gluta-
mic acid (E) seen at a frequency of only 12.74%. An analysis
of the combination of both polymorphisms, alanine at po-
sition 150 and glutamic acid at position 206
(A150V_K206E), was present in <4% of the population,
making this a rare combination.
We examined the impact of the polymorphisms of in-
terest in pretreatment samples from a cohort of HCV
Figure 2. 3-Dimensional model of the HCV
polymerase NS5b (A, front; B, back; C, top)
derived from the JFH-1 crystal structure with
the location of the polymorphisms of interest
shown in purple. The structure in the center
represents a bound RNA strand. PDB crystal
structure ID: 4WTG. Structure was annotated
using the Chimera software. dNTP, deoxyribo-
nucleotide triphosphate; dsRNA, double-
stranded RNA.
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LIVERgenotype 3 patients who were treated using SOF and RBV,
with or without pegylated IFN (BOSON trial).22 In this
cohort, the frequency of the polymorphisms seen in patient
9 (above) were too low to provide meaningful data (indi-
vidually all were present in <10% of the population and
combinations were present in fewer than 10 patients), but
A150V and K206E polymorphisms were common
(Supplementary Figure 2C). We investigated the association
between A150V and K206E amino acid substitutions and
outcome (Supplementary Figure 2D). To limit the impact of
population structure and host genetics, we investigated
patients with self-reported white ancestry and genotype 3a
virus (n ¼ 411 patients). At site 150 in NS5b protein,
the most commonly observed amino acids were valine
(42% ¼ 170/407) and alanine (38% ¼ 156/407). We also
observed threonine (n ¼ 13%), isoleucine (4%), serineFigure 3. Huh7.5-SEC14L2 cells transiently transfected (by el
constructs with the NS5b polymorphisms from patient 9 (see Tab
was determined by luciferase assay, normalized to a sample 4 h
SOF non-response, a replicon containing the S282T NS5b m
polymorphisms from patient 9 to SOF sensitivity. IC50 values
centration that affected a 50% reduction in HCV RNA and are su
plotted ± SEM. The above is representative of at least 3 indepe(1.5%), glycine (1%), and asparagine (0.5%). As valine was
the most common variant identified in our phenotypic
studies, we analyzed isolates carrying valine or alanine at
this site (n ¼ 326). In logistic regression multivariate
analysis accounting for population structure of virus
and host (using principal component analysis), host IFNL4
genotype (CC vs non-CC), cirrhosis status, and previous
treatment status, the polymorphism A150V was associated
with an increase in relapse (P ¼ .0027; SVR in
patients whose virus carries alanine at position 150 ¼ 88%
[n ¼ 138/156] and valine at position 150 ¼ 71% [n ¼ 121/
170]) (Supplementary Figure 1C).
At site 206 in NS5b, the most commonly observed amino
acids were lysine at 79% (n ¼ 323/410) and glutamic acid
at 13% (n ¼ 54/410). We also observed glutamine (5%),
threonine (2.4%), and, rarely, asparagine and aspartic acid.ectroporation) with luciferase-containing HCV (S52-replicon)
le 1). Cells were treated with SOF for 72 hours and replication
ours post electroporation for each construct. As a control for
utation was included. Panels A–E indicate the effect of the
with 95% CIs were calculated by determining the drug con-
mmarized in Table 2. Mean values per drug concentration are
ndent experiments.
Table 2.50% Inhibitory Concentration Values of Sofosbuvir Against Identified Hepatitis C Virus Genotype 3a Polymorphisms
Compared With the Wild-Type S52 Replicon
S52 Replicon SOF IC50 (95% CI), mM Fold change in SOF IC50 Luciferase levels, % of Wt, mean ± SEM
Wt 0.63 (0.4–0.99) 1.00 100.00 ± 10.33
K100R 1.26 (0.64–2.5) 2.00 72.45 ± 13.18
A150V 4.88 (2.7–18.9) 7.75 98.17 ± 11.59
G188D 6.84 (2.47–18.9) 10.86 74.02 ± 17.11
K206E 5.25 (2.96–9.33) 8.34 59.35 ± 21.05
T213N 0.8 (0.85–3.43) 1.27 108.20 ± 18.19
N244I 10.32 (5.28–20.16) 16.38 55.95 ± 13.01
K100Rþ G188D 19.91 (8.45–46.89) 31.80 40.96 ± 14.51
A150V þ K206E 22.54 (12.47–40.74) 35.77 120.4 ± 17.75
S282T 45.15 (6.04–161.6) 71.67 67.85 ± 18.88
NOTE. IC50 values for SOF for each replicon construct are shown with 95% CIs. Fold-change in IC50 for SOF was calculated
for each mutated construct using the unmodified Wt S52-replicon as a baseline. Relative luciferase levels compared to the Wt
replicon construct were also included to measure the replication capacity of each replicon.
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isolates carrying lysine or glutamic acid for analysis
(n ¼ 377). We did not observe an association between the
polymorphism K206E and treatment outcome (P ¼ .26; SVR
in patients whose virus carries K206 ¼ 79% [n ¼ 255/323]
and E206 ¼ 83% [n ¼ 45/54]).Figure 4. Huh7.5-SEC14L2 cells were transiently transfected
replicon) with Wt, 150V, and 206E, individually and in combi
replication was measured using a luciferase assay and normalize
Panels A–C indicate the effect of the polymorphisms (A150V an
with 95% CIs were calculated by determining the drug concentra
per drug concentration are plotted ± SEM. The above is represTo look at the interactions among the 3 sites, we
included isolates carrying A or V at site 150 and K or E at
site 206 in NS5b protein (AE ¼ 25, AK ¼ 120, VE ¼ 16, and
VK ¼ 139). Using the same multivariate logistic regression,
including an interaction term between the 2 polymorphisms
A150V and K206E, we observed no significant interaction(by electroporation) with luciferase containing HCV (S52-
nation. Cells were treated with SOF for 72 hours and HCV
d to a sample 4 hours post electroporation for each construct.
d K206E) from patients 10–14 on SOF sensitivity. IC50 values
tion that affected a 50% reduction in replication. Mean values
entative of at least 3 independent experiments.
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LIVERbetween the 2 substitutions (P ¼ .13). Analyzing the hap-
lotypes, we observed the lowest rate of SVR in patients
whose virus carries the VK haplotype at 68% (n ¼ 95/139),
while the other haplotype carriers all had higher rates of
SVR (AK ¼ 89% [n ¼ 107/120], AE ¼ 88% [n ¼ 22/25], and
VE ¼ 81% [n ¼ 13/16]).
Structural Relevance of the Identified
Polymorphisms in Hepatitis C Virus NS5b
To examine the structural significance of the observed
polymorphisms, we plotted their location on a structural
model of the HCV NS5b RNA polymerase. The crystal
structure of the HCV genotype 3 NS5b has not been deter-
mined and we therefore used the well-established structure
for strain JFH-1, a genotype 2a isolate.23 Most substitutions
were located within domains I (“fingers”) and II (“palm”) of
the protein (Figure 2). The palm domain contains the cata-
lytic triad that forms the enzymatic active site. Highly
conserved residues, crucial for the active site, are located at
positions D220, D225, G317, D318, and D319.24,25 While
none of our identified positions are part of or adjacent to
residues of the active site, 2 positions are in close proximity,
K206E and T213N. The structural model shows that K206
(LYS-206) forms part of an a-helix close to the RNA binding
cleft, but not directly within it. This residue is also close to a
domain previously reported crucial for the RNA binding
capacity of NS5b.26 Thr-213, however, is more distant from
the catalytic site of the polymerase in the model.
The catalytic activity of NS5b is modulated by a direct
interaction with NS5a.27,28 This stimulates activity of the
polymerase but can also inhibit activity in a dose-dependent
manner.27 Specific domains on the NS5b are crucial for this
interaction and include residues 143–145, 149–155, 365–
371, and 382–388. A150V is located within one of these
domains, which may affect NS5a binding and thereby
potentially modulate the catalytic activity of NS5b. From a
structural context, position 150 in NS5b is found within the
finger domain—between the lysine-rich ends of the finger on
a flexible loop that protrudes from the surface. This motif is
highly conserved at its N- and C-termini, where a number of
amino acids with positively charged side chains interact with
incoming nucleotide triphosphates transiting to the active
site and nucleotide binding pocket. This region is highly
variable in sequence and likely structure. In the crystal
structure of the closed conformation of the JFH-1 strain
NS5b, residue 150 is on the end of a loop, protruding from the
molecule over the nucleotide entry tunnel. Note that JFH-1
NS5b has a similar sequence in the finger-loop domain to
genotype 3a. This loop is likely to be dynamic and not highly
structured, as observed in flaviviruses and human immuno-
deficiency virus, where nucleotide interactions can trigger
conformational changes in the finger domain, bringing it
closer to the body of the polymerase toward the active site.29
Effect of NS5b Polymorphisms on Drug
Sensitivity
We examined the impact of the polymorphisms in
modified HCV genotype 3 sub-genomic replicons. Theidentified polymorphisms were introduced into the S52
genotype 3 replicon30 and the nucleotide changes were
confirmed by Sanger sequencing. The unique pattern of
polymorphisms seen in patient 9 were associated with
changes in sensitivity to SOF (Figure 3A–E and Table 2) and
RBV (Supplementary Figure 3A–E and Supplementary
Table 2). The largest impact on SOF sensitivity by an indi-
vidual polymorphism was seen with N244I (a 16-fold
increase in 50% inhibitory concentration [IC50] with non-
overlapping CI). The K100R and T213N polymorphisms
had a minimal impact on SOF sensitivity. The G188D poly-
morphism had a more marked effect (10-fold increase in IC50
with non-overlapping CI), but in combination with the K100R
polymorphism, the effect on SOF sensitivity was increased
and comparable to the level seen with the S282T variant. It
should be noted that the combination of K100R and G188D
and the N244I replicons had the greatest reduction in
replication efficiency, as measured by relative luciferase
(RLU) levels in comparison to the wild type (Wt). Attempts to
generate viable replicons with further combinations of
polymorphisms were not successful, precluding a full anal-
ysis of all of the variants and their interactions, but it is clear
that combinations of mutations in HCV NS5b can modify the
SOF response. Some of these polymorphisms (noticeably
K100R) also reduced the effects of RBV. Given that patient 9
also had the Y93H NS5a polymorphism (Supplementary
Table 1), known to modify the response to NS5a inhibitors,
we speculate that multiple polymorphisms are required to
influence the clinical response to short courses of SOF-based
therapies. Intriguingly, patient 9 cleared the virus with a
prolonged course of SOF/DAC and RBV therapy.
Analysis of the A150V and K206E Polymorphisms
Examination of the common A150V and K206E poly-
morphisms in a transient replicon assay (Figure 4 and
Table 2) individually showed a reduced sensitivity to SOF
(8-fold) with non-overlapping CI. The combined poly-
morphisms (A150V and K206E) further reduced sensitivity
to SOF (>35-fold) with non-overlapping CI. The effect of
these polymorphisms on RBV sensitivity ranged from 10-
fold for K206E to >40-fold change in IC50 for A150V, but
in combination, the effect was enhanced (approximately 70-
fold change in IC50 with non-overlapping CI)
(Supplementary Figure 4 and Supplementary Table 2).
The transient subgenomic replicon assays demonstrated
that NS5b polymorphisms A150V and K206E impact the
sensitivity of the polymerase to both SOF and RBV. We
sought to confirm our findings in an infectious HCV model,
which covers all stages of the viral lifecycle and may be
more representative of the situation in vivo. The A150V
and K206E polymorphisms were engineered individually
and in combination into the DBN3acc virus,31 and the
presence of the substitution was confirmed by Sanger
sequencing. Cells were transfected to generate virus stocks,
and the presence of the DBN3acc was confirmed by
immunofluorescence for NS5a (Supplementary Figure 5).
The viral stocks generated were analyzed by NGS up to 26
days in culture and no nucleotide changes or new cell
culture adaptations were observed (data not shown). The
Figure 5. Sensitivity of
HCV genotype 3 viruses to
SOF, RBV, and DAC,
comparison between the
Wt and polymorphisms of
interest. Huh7.5 SEC14L2
cells were infected with
the indicated HCV geno-
type 3 viruses at an multi-
plicity of infection of 0.2
for 72 hours before treat-
ment with serial dilutions
of SOF (A), RBV (B), or
DAC (C). After 24 hours of
drug treatment, the
cells were harvested (72
hours for RBV) and
HCV quantified by reverse-
transcription quantitative
polymerase chain
reaction. Concentration–
response curves were
calculated. IC50 values
with 95% CIs were calcu-
lated by determining the
drug concentration that
affected a 50% reduction
in HCV replication. Mean
values per drug concen-
tration are plotted ± SEM.
Results show a mean of 2
independent experiments
done in duplicate.
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A150V, K206E, and their combination were assessed over a
72-hour period. Up to 48 hours, the presence of poly-
morphisms did not have a significant impact on the infec-
tivity, however, by 72 hours, a reduction in HCV RNA was
observed in all viruses with the polymorphisms compared
to the Wt (Supplementary Figure 6A). To further assess
whether either the A150V or K206E polymorphism altered
the viral fitness, the individual viruses were mixed with Wt
virus at an equal ratio based on infectivity titer and used to
infect naïve cells.32 Next-generation sequencing analysis of
the infected cells over 72 hours demonstrated that theintroduced polymorphisms did not confer a fitness advan-
tage to the viruses, no virus dominated at any time point
(Supplementary Figure 6B–C), suggesting that the observed
changes in drug sensitivity were not due to enhanced viral
replication.
Next, we tested the sensitivity of our modified viruses to
SOF, RBV, and DAC. We found that these viruses demon-
strated a higher sensitivity to SOF than sub-genomic repli-
cons yet the A150V and K206E mutations independently
and in combination reduced the sensitivity to SOF
(Figure 5A), confirming our previous findings. Additional
reductions in sensitivity to RBV were also observed
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as in previous replicon assays. Viruses were also assessed
for their response to the NS5a inhibitor DAC (Figure 5C), no
difference in sensitivity to either polymorphism, expressed
individually or in combination in comparison to the Wt was
observed. Together these data indicate that the poly-
morphisms A150V and K206E in the HCV NS5b polymerase
individually and in combination cause a significant alter-
ation in sensitivity to SOF in both replicon and infectious
models.Discussion
SOF is a central component of some of the most effective
drug regimens for the treatment of hepatitis C and a full
understanding of its strengths and weaknesses will be
important to ensuring it continues to be deployed appro-
priately. This is of particular importance, given the avail-
ability of alternative regimens for HCV genotype 3 that are
based on the protease inhibitor glecaprevir.33 Studies on
SOF “resistance” have been hampered by the extraordinary
efficacy of the drug, which has led to very few treatment
failures, although some very rare polymorphisms that can
modify response, particularly in genotype 1 infection, have
been identified.34 Viral resistance is normally identified by
post-treatment emergence of variants that can be shown to
reduce drug efficacy in laboratory studies. However, the
marked variability of hepatitis C with multiple, rapidly
evolving polymorphisms makes identification of “resistance-
associated substitutions” difficult and very large cohorts are
required. This is illustrated by the initial trial examining 8
weeks of SOF plus ledipasvir for 8 weeks,35 which did not
suggest any impact of resistance-associated variants in the
NS5a protein, but subsequent analysis of more than 2000
patients from multiple studies showed that variants in the
NS5a protein modify response.36 It is thus very difficult to
evaluate the mechanisms underlying a failure to respond to
SOF-based regimens with classical approaches and with the
increasing efficacy of combining SOF with a protease in-
hibitor and a NS5a inhibitor it is likely that identifying
motifs associated with failure will require massive patient
cohorts. It is believed that SOF does not generate significant
viral resistance and can therefore be used successfully for
retreatment regimens. This hypothesis has been confirmed
by clinical studies in which patients who failed to respond to
SOF were successfully retreated with a combination of SOF,
velpatasvir, and voxilaprevir, although a tiny number of
patients did not achieve a virologic response,8 and this was
most marked in patients with genotype 3 HCV and cirrhosis
who had failed to respond to an NS5a-containing regimen,
where response rates were 93%. Given the difficulties of
identifying SOF “resistance” by conventional sequence-
based assays, we have adopted a phenotyping approach
that has allowed us to examine previously unexplored viral
variants that impact on the response to SOF.
SOF is a potent pan-genotypic antiviral drug, but patients
infected with genotype 3 HCV respond less well than other
genotypes, and response to therapy is further reduced bythe presence of cirrhosis or previous failure to respond to
IFN. We studied patients who failed to respond to SOF-
containing regimens that are now known to be inade-
quate. Our analysis shows that reduced response to SOF
may occur if multiple viral polymorphisms are combined.
The strength of this study is the use of multiple
different phenotypic analyses on viral variants of interest
coupled with a genetic analysis in a cohort of patients who
received SOF-only therapies without potent NS5a in-
hibitors. The use of different assay systems (capture-fusion
replication, viral replicons, and modified viruses) showed
that different assays have different characteristics and the
efficacy of SOF in vitro is heavily dependent on the assay
deployed.
We do note that specific IC50 values for antiviral drugs
tested in our assay against the recently characterized
DBN3acc virus differ from those published previously,31 we
attribute this difference to our use of RNA copies to measure
viral response as opposed to quantifying cells positive for
viral proteins. We found some reduction in replication ef-
ficiency in the modified replicons, however, the maximum
changes were of a similar magnitude to those seen with the
S282T variant,13 and we therefore do not believe that they
significantly alter our conclusions that these mutations
impair the efficacy of SOF. Previous studies suggest that an
increase in replicative fitness can modify antiviral sensi-
tivity,32 but as the modified viruses we generated in this
study demonstrated no significant increase in replicative
fitness, we can exclude this as an explanation for the
observed changes in drug sensitivity.
Collectively, our observations may help to explain why
SOF polymorphisms that emerge during therapy do not
appear to affect the sensitivity to SOF in vitro.13,15 Indeed,
recent studies that modeled SOF resistance in vitro identi-
fied variants that had a significant impact on viral sensitivity
to SOF, but were rarely found in clinical isolates.31 It is
unclear which of the different assays most accurately re-
flects the conditions in patients, but in this study we found a
very consistent pattern of response—in all of the assays, the
same polymorphisms had similar effects, although the
magnitude differed quite markedly in the different assays.
The main weakness of this study is the use of samples from
treatment regimens that have been superseded by more-
potent drug combinations. However, treatment failure
with the new, triple-therapy regimens is rare, and an anal-
ysis of the outcomes of such treatments will require very
large, real-world cohorts that are only now beginning to
emerge.
Clinically, our data show that unusual viral poly-
morphisms can impair the response to SOF. For treatment-
naïve patients, responses to SOF-based treatments are so
effective that any impact of these viral variants is likely to be
minimal, and we would not recommend that such patients
undergo pretreatment “resistance” testing. For patients who
have been exposed to multiple drug regimens (including IFN
and NS5a inhibitors, which can lead to resistance-associated
polymorphisms), we speculate that the polymorphisms
identified here might be of significance, and we suggest that
September 2019 HCV G3 Response to Sofosbuvir 703pretreatment viral sequencing may be useful in selecting the
optimal regimen for such patients. Further studies in large
cohorts of patients exposed to diverse treatment regimens
will no doubt identify the small cohorts of patients who
require sophisticated virologic analysis before therapy.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology
at www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2019.05.007.RReferencesCL
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Supplementary Methods
Cells and Viral Phenotyping
Huh7.5-SEC14L2 cells (kind gift from P. Simmonds, Ox-
ford, UK) were propagated in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum. ThP1
cells were propagated in RPMI supplemented with 10%
fetal calf serum. Cytokines used for ThP-1 stimulation were
phorbol 12-myristate 13-acetate (Sigma-Aldrich, Dorset,
UK) and interferon gamma (Invitrogen, Paisley, UK). SOF
was kindly provided by Gilead Sciences (Foster City CA),
DAC by Bristol-Myers Squibb (New York, NY), and RBV by
Sigma Aldrich (St Louis, MO). All antiviral drugs were
reconstituted in dimethyl sulfoxide.
Viral phenotyping was performed using the capture-
fusion viral replication assay, as described previously.1
Briefly, THP-1 cells were seeded into 6-well plates (106
cells/mL) and maintained for 18 hours, with or without the
addition of IFN gamma (10 ng/mL) and phorbol 12-
myristate 13-acetate (200 ng/mL). Cells were washed 3
times and the medium replaced with RPMI/2% fetal calf
serum and patient serum (1 HCV IU/cell). After incubation
at 37C for 18–24 hours, the supernatant was removed and
cells were washed. Adherent cells were removed using a cell
scraper and Huh7.5 cells added at a 1:1 ratio. Cell fusion
was performed as above. The fused cells were seeded into 6-
well plates at a density of 105 cells/mL and maintained at
37C in the presence or absence of antiviral drugs for 3
days.
HCV RNA was quantified by reverse-transcription poly-
merase chain reaction (PCR). Total RNA was extracted with
TRIzol (Invitrogen) and quantified using RiboGreen (Invi-
trogen), according to the manufacturer’s instructions. One-
step reverse transcription PCR (QuantiTect Virus Kit Qia-
gen, Crawley, UK) and TaqMan Gene Expression Assay HCV
primer and probe (Applied Biosystems, Paisley, UK) were
used for quantification. PCRs were performed in triplicate.
Absolute quantification of HCV RNA was performed by
including serial dilutions of an RNA standard in each PCR
run and expressed relative to total sample RNA.
To assess cytotoxicity of antiviral drugs, cells were
seeded in a 96-well plate in triplicate and incubated in the
presence of a serial dilution of drugs for 72 hours. A 10X
AlamarBlue reagent was added directly to the cell media
and incubated for 3 hours at 37C. Fluorescence at excita-
tion wavelength of 560 nm and emission wavelength of
590 nm was then quantified.
Sequencing
Sequencing of patient samples by Metagenomic and
Target Enrichment was performed after RNA extraction
from 200 mL plasma (Agencourt RNAdvance Blood kit;
Beckman Coulter, Brea, CA), eluted into 11 mL water, and
reverse transcribed (SuperScript III; Invitrogen) with
random hexamers and a Second Strand Synthesis kit (New
England Biolabs, Ipswich, MA). Library preparation was
performed with the KAPA Library Prep kit (KAPA
Biosystems, Wilmington, MA) with index tagging by 16 cy-
cles of PCR using KAPA HiFi HotStart (KAPA Biosystems)
and custom-synthesized multiplex oligos. Libraries were
quantified by Qubit (ThermoFisher, Waltham, MA) and
TapeStation (Agilent), pooled at equimolar concentrations
for sequencing on the Illumina MiSeq (v3 chemistry; Illu-
mina, San Diego, CA). For target enrichment, pooled libraries
were enriched by the NimbleGen SeqCap EZ System (Roche,
Basel, Switzerland), followed by sequencing on the Illumina
MiSeq platform using v3 chemistry. Variant analysis was
performed after Fastq file quality assessment using FastQC
and Sam files were created by mapping against whole-
genome HCV reference sequences. Assemblies were
viewed using UGene and positions of interest identified in
the GenBank HCV strain H77 polyprotein gene (accession
no. AF011751). Each reference was aligned against HCV
strain H77 to standardize the positions of interest and total
base counts were identified at the variant positions.
Hepatitis C Virus Target Enrichment
RNA was isolated from 200 mL of cell culture superna-
tant using the RNAdvance Blood extraction kit (Beckman
Coulter) and collected in 27 mL water. After conversion of
RNA to double-stranded DNA, libraries were prepared for
Illumina sequencing using the KAPA DNA LTP Library
Preparation Kit (Roche), and NEBNext Multiplex Oligos for
Illumina (New England Biolabs). Libraries were quantified
using Qubit dsDNA HS Assay Kit (Invitrogen) and size dis-
tribution assessed using Agilent TapeStation with D1K High
Sensitivity Kit (Agilent); libraries were normalized accord-
ingly to viral load and mass. A 500-ng aliquot of the pooled
library was enriched using SeqCap EZ Developer Probes
(Roche) following manufacturer’s protocol. After a 14-cycle
post-enrichment PCR, the cleaned pool was sequenced with
151 base-paired end reads on an Illumina NextSeq cartridge,
with resulting reads characterized by Q30 >87%.
Site-Directed Mutation Primers
Outer NS5b primers encoding XhoI and XbaI restriction
sites at the 50 and 30 end of NS5b
S52-5b XhoI F TGCCTCCTCTCGAGGGAGAG
S52-5b XbaI R GGTCGACTCTAGACATGATCTGC
Overlapping primers designed to introduce the specified
amino acid change in NS5b
S52-5b-K100R-F GTCCCTCCTCACTCTGCCCGGTCGAGG
TTCGGGTATAGTGCGAAGG
S52-5b K100R-R CCTTCGCAC
TATACCCGAACCTCGACCGGGCAGAGTGAGGAGGGAC
S52-5b-G188D-F GTCAATTGAGACGATGGATTCCGCTTAT
GGATTCCAATACTC
S52-5b-G188D-R GAGTATTGGAATCCATAAG
CGGAATCCATCGTCTCAATTGAC
S52-5b-A150V-F GTTTTGTGTGGACCCCGTTAAAGGGGGC
CGC
S52-5b-A150V-R GCGGCCCCCTTTAACGGGGTCCACACAA
AAC
S52-5b-K206E-F CGGGTCGAACGTCTACTGG
AGATGTGGACCTCAAAG
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S52-5b-K206E-R CTTTGAGGTCCACATCTCCAGTAGACGT
TCGACCCG
S52-5b-T213N-F GAAGATGTGGACCTCAAAGAAAAACCC
CTTGGGGTT
S52-5b-T213N-R AACCCCAAGGGGTTTTTCTTTGAGG
TCCACATCTTC
S52-5b-N244I-F GGAGATATATCAATGCTGTATCCTTGA
ACCGGAGGC
S52-5Bb-N244I-R GCCTCCGGTTCAAGGATACAGCA
TTGATATATCTCC.
Immunofluorescence
Cells were plated onto glass cover slips at 1  104/cm2
12–14 hours before experiment. Cells were then washed
with phosphate buffered saline and fixed in ice-cold meth-
anol at –20C for 20 minutes and then washed in phosphate
buffered saline and blocked with 3% fetal bovine serum for
1 hour at room temperature. The sheep polyclonal anti-
NS5a (kind gift from Mark Harris, Leeds University) was
diluted in blocking buffer at 1:1000 and cells were incu-
bated for 1 hour at room temperature. Unbound primary
antibody was removed by 3 washes with 1X phosphate
buffered saline before incubation with Alexa Flour 488
donkey anti-sheep secondary antibody diluted to 1:1000 for
1 hour at room temperature. Cells were then incubated with
40,6-diamidino-2-phenylindole (1:1000) for nucleus
visualization.
Relative Fitness Assay
Growth-competitions experiments were established be-
tween the DBN_WT and DBN_A150V or DBN_K206E in
Huh7.5 cells. Huh7.5 cells (4 105) were infected with a 1:1
mixture of the 2 competing viruses, based on their infec-
tivity titers (total, 1.2  104 median tissue culture infectious
dose: multiplicity of infection of 0.03 median tissue culture
infectious dose/cell), following Sheldon et al.2 RNA was
extracted from the initial mixture (0 hours) and from cells at
24, 48, and 72 hours post infection. PCR products were
generated for the regions of interest with the addition of
common sequence tags CS1 and CS2 to allow for the addi-
tion of a sample index barcode.
A150V-F
GACACCACAACCCCAATTCCAACTACCATAATGGCG,
A150V-R
CACGTCATATAGGGCACGTTTCTCACAGACACGCACCCCC,
K206E-F
GTCTGCCTACGGATTCCAATACTCGCCTCAACAGCG,
K206E-R
CTGTTCAGTGACAGTCGAGTCAAAGCAGCGGGTGTC
Fastq files were decompressed and the grep command
line tool used to perform a count analysis on each sample to
determine the number of counts for each variant. A flanking
region was used upstream and downstream of the variant
site to ensure high sequence similarity. The following se-
quences were used:
A150V-alanine: GACCCCGCTAAGGGG
A150V-valine: GACCCCGTTAAGGGG
K206E-lysine: CTGCTGAAGATGTGG
K206E-glutamic-acid: CTGCTGGAGATGTGG
Counts for each sample were tabulated and a percentage
of the total number of reads calculated. Any sample with
<15 reads in total was considered a fail and these data were
not reported.
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Supplementary Figure 1. Huh7.5 cells were incubated with a
serial dilution of RBV for 72 hours in triplicate. AlamarBlue
reagent was added for 3 hours and fluorescence intensity
was assessed as a measure of cytotoxicity.
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Supplementary
Figure 2. (A) HCV geno-
type 1–7 amino acid se-
quences were aligned and
the table shows the amino
acid at the positions of
interest and compared to
the gt3a reference
sequence. (B) Alignment
of 1200 HCV genotype 3a
sequences from the HCV-
GLUE database identi-
fying the minor variants at
each position of interest.
Legend designates the
color code for each amino
acid. (C) Analysis of the
NS5b polymorphisms in
the BOSON cohort, the
prevalence of the NS5b
polymorphisms was
assessed from >500 viral
sequencing samples ob-
tained from the BOSON
cohort. (D) Each mutation
was tested to assess
whether the frequency
was significantly different
between SVR and non-
SVR samples. Fre-
quencies were analyzed
using Fisher’s exact test.
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Supplementary Figure 3. Huh7.5-SEC cells transiently transfected (by electroporation) with luciferase containing HCV (S52-
replicon) constructs with the indicated NS5b polymorphisms were assessed. Cells were treated with RBV for 72 hours and
replication was measured using a luciferase assay, normalized to a sample 4 hours post electroporation for each construct.
Panels A–E indicate the effect of the polymorphisms from patient 9 to RBV sensitivity. The above is representative of at least 3
independent experiments. Relative luciferase units (RLU).
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Supplementary Figure 4. Huh7.5-SEC cells transiently transfected (by electroporation) with luciferase containing HCV (S52-
replicon) constructs with the indicated NS5b polymorphisms were assessed. Cells were treated with RBV for 72 hours and
replication was measured in a luciferase assay, normalized to a sample 4 hours post electroporation for each construct. Panels
A–C indicate the effect of the polymorphisms from patients 10–14 on RBV sensitivity. The above is representative of at least 3
independent experiments. Relative luciferase units (RLU).
704.e6 Wing et al Gastroenterology Vol. 157, No. 3
Supplementary
Figure 5. Huh7.5-
SEC14L2 cells transfected
with the viral constructs
were stained for the HCV
NS5a protein (green) by
immunofluorescence 7
days post transfection to
confirm establishment of
replication complexes.
Mock transfected cells
were included as a nega-
tive control.
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Supplementary
Figure 6. (A) Naïve
Huh7.5-SEC14L2 cells
were infected with Wt and
DBN virus with the poly-
morphisms of interest at a
multiplicity of infection of
0.05. Samples were taken
at the indicated time
points for quantification of
HCV RNA by reverse-
transcription quantitative
polymerase chain reaction.
Data presented are repre-
sentative of 2 independent
experiments and analyzed
using a Mann-Whitney U
test. Graph depicts mean
± SEM. (B, C) An equal
inoculum of the Wt and
mutant virus was used to
infect the cells (multiplicity
of infection ¼ 0.03 median
tissue culture infectious
dose), the relative amounts
of the competing viruses
were determined by next-
generation sequencing at
0, 24, 48, and 72 hours
post infection and the
percent of Wt (alanine at
150 or lysine at 206) is
shown.
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Supplementary Table 1.Details of clinical samples used in the capture-fusion phenotyping assay
Patient no. Therapy Outcome
SOF/RBV
sensitivity
Age,
y Sex Cirrhosis
Previous
IFN
treatment
Baseline
viral load,
IU/mL
NS5A RAS,
baseline
1 SOF/DAC/RBV SVR Sensitive 59 M Decompensated Yes 2,178,912 —
2 SOF/VEL SVR Sensitive 32 F Compensated No 5,992,729 —
3 Ombitasvir/paritaprevir/
ritonavirþSOF
SVR Sensitive 61 F Non-cirrhotic Yes 2,301,777 —
4 SOF/DAC SVR Sensitive 59 F Non-cirrhotic No 2,663,854 —
5 SOF/LDV/RBV Relapse Sensitive 47 M Decompensated No 2,321,679 —
6 SOF/DAC/RBV Relapse Sensitive 49 M Decompensated Yes 1,913,455 —
7 SOF/LDV/RBV Relapse Sensitive 52 M Decompensated Yes 808,776 —
8 SOF/LDV Relapse Sensitive 49 M Decompensated No 3,100,000 —
9 SOF/DAC/RBV Relapse Insensitive 48 M Decompensated No 1,585,601 Y93H
10 SOF/LDV/RBV Relapse Insensitive 54 M Decompensated No 255,934 —
11 SOF/LDV/RBV Relapse Insensitive 56 M Non-cirrhotic (transplant graft) Yes 2,362,045 —
12 SOF/DAC/RBV Relapse Insensitive 58 M Decompensated Yes 902,000 —
13 SOF/LDV/RBV Relapse Insensitive 43 M Decompensated No 5,670,819 NA
14 SOF/LDV/RBV Relapse Insensitive 50 M Decompensated Yes 570,000 Y93H
NOTE. Details of the samples used in the capture fusion assay (Figure 1 and Table 1). Data include treatment, clinical outcome,
age, sex, disease status, and baseline viral load.
F, female; LDV, ledipasvir; M, male.
Supplementary Table 2.50% Inhibitory Concentration Values of Ribavirin Against Identified Hepatitis C Virus Genotype
3a Polymorphisms Compared With the Wild-Type S52 Replicon
S52 replicon RBV IC50 (85% CI), mM Fold-change in RBV IC50 Luciferase levels, % of Wt, mean ± SEM
Wt 0.70 (0.47–1.05) 1.00 100.00 ± 10.33
K100R 23.61 (9.96–55.95) 32.85 72.45 ± 13.18
A150V 28.03 (17.14–45.83) 40.04 98.17 ± 11.59
G188D 15.19 (4.94–46.67) 21.70 74.02 ± 17.11
K206E 7.40 (4.66–11.75) 10.57 59.35 ± 21.05
T213N 6.12 (3.58–10.54) 8.74 108.20 ± 18.19
N244I 1.49 (0.78–2.86) 2.13 55.95 ± 13.01
K100RþG188D 7.27 (5.15–10.25) 10.35 40.96 ± 14.51
A150VþK206E 48.69 (20.81–113.9) 69.55 120.4 ± 17.75
NOTE. The calculated IC50 values with 95% CIs and the fold-change compared to the Wt replicon from Supplementary
Figures 3 and 4 were replicons were treated with RBV, are summarized. Relative luciferase levels compared to the Wt
replicon construct for each polymorphism were also included.
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